ATLAS fair value
$56.97
Below fair value · 39% discount
Indivior Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ
Prices as of Oct 27, 2026 · USD
$56.97
Below fair value · 39% discount
50%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates Indivior Pharmaceuticals's fair value at about $56.97 per share (reasonable range: $46.59 to $68.96). At $34.72, the stock trades 39% below it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is low. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Indivior Pharmaceuticals a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $32.60 and $37.00; in 9 out of 10, between $29.13 and $41.40. Estimated annual volatility is 32%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Indivior Pharmaceuticals sits below fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks INDV has traded between $24.28 and $42.81. Today it is 18.9% below that high and 43% above its low.
On the business: revenue grew 4.3% year over year; net margin is 17.0%; it trades at 11.7 times earnings.
Its beta is 1.11: it moves roughly in line with the market.
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on medicines for opioid use disorder and related substance use disorders.
Want to see everything about Indivior Pharmaceuticals?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About $56.97 per share according to ATLAS (reasonable range: $46.59 to $68.96). With the stock at $34.72, it is 39% below it.
50%: close to a coin flip. In half of the simulated outcomes, INDV ends the month between $32.60 and $37.00.
Indivior Pharmaceuticals's market capitalization is $4.2B. Its price-to-earnings (P/E) ratio is 11.7: you pay $11.7 for each $1 of yearly earnings.
ATLAS estimates annual volatility at 32%. In a typical month, half of the outcomes end between $32.60 and $37.00.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy